Raman has advised on healthcare business development and financing transactions totalling over $70 million. He founded ATPBio in 2002, and has built a substantial network with CEO/ CFO level in biotech and healthcare companies and with senior members of the investment community. Operational roles include Head of Corporate Development at a UK biotech, F2G Ltd. Previously he was a senior biotech analyst at a London investment bank, where he identified several successful healthcare private equity investment opportunities. Raman qualified as a medical doctor from the Queens Medical Centre, University of Nottingham, UK. He practiced clinical medicine for six years in A&E and general medicine. Raman also writes a blog on trends in biotech business, "ATPblog". This is read by over 1000 senior level life science professionals including CEOs, CFOs, VCs, directors and entrepreneurs.

Ted has more than 30 years of business experience including 10 years as an officer at Burson-Marsteller, a global communications and lobbying firm. His life sciences expertise includes biotechnology, medical technology and medical devices. He is experienced in mergers & acquisitions, crisis management and international development. Ted specializes in working with UK and EU companies to establish a US presence. Currently, Mr. Agne is working with the Golden Triangle Partnership, a collaboration of the UK’s Oxford, London and Cambridge biotech/medtech clusters, in creating partnering and other business development opportunities with US companies. Earlier, he advised on the expansion and introduction of Oxxon Therapeutics, Domantis and Speedel to the US. In 1987, Ted established The Communications Strategy Group (CSG), a consulting firm to help new and early stage companies manage their corporate/financial positioning and business development. Prior to forming CSG, he was Vice President, Corporate Relations at Avondale Industries, a $1.2 billion industrial conglomerate, and its subsequent company, Connell Limited Partnership, Boston.

Jeff has considerable expertise in financial and operational management, including 11 years at Partner /Director level. He is a founder and Managing Partner of Kelly, Bamman & Partners, Ltd., a boutique investment bank. He has participated in raising over $30 million in private equity and played a key role in the licensing of several drug programs from a U.S. biotech in order to structure a spin-out. He also has been involved in M&A analyses and evaluation, and implementation of operational systems for finance, accounting, personnel and IT. Previously, he was the Vice President of Global Support Services for F5 Networks where he grew the Services Organization from 30 to a team of 125 professionals and quadrupled service revenue. Previously, he has held positions as Director of Contract Consulting Services with Excell Data Corporation, and a variety of senior positions at Digital Equipment Corporation. Jeff earned his MBA in Finance with the Anderson School of Management at UCLA, and is a former CPA.

David Cavalla has 24 years experience in various senior scientific and commercial roles within the pharmaceutical industry. He is currently involved with a number of biotech companies at Board level, principally Numedicus Limited and Switch Pharma Group plc. He is also a member of the Scientific Advisory Board of Peakdale Molecular Ltd. Previously he was founder and CEO of Arachnova Ltd, a company focused on therapeutic switching, from which he exited as a result of a trade sale; previous affiliations included Glaxo Group Research Ltd and Napp Research Centre. He has advocated the virtual strategy of pharmaceutical R&D and drug repurposing (secondary uses for existing drugs) to improve R&D efficiency. He is on the editorial board of Drug Discovery Today. He was Chairman of the Society for Medicines Research. He trained at Cambridge University and the NIMH, Washington, DC. He is author/inventor of over 70 published papers and patents."

Nigel Crockett, has more than 18 years of commercial experience in the pharma-biotech sector, spanning Europe, the US and Asia, with particular expertise in small molecule and biologicals, in–licensing and out-licensing, early-stage R&D collaborations, medical devices, company financing and acquisitions and a very highly respected worldwide network of industry and academic contacts. In 2005 Nigel founded Tukan Partners Ltd to provide hands-on, transactional, commercial expertise for biotech clients. He is also a director of UK-based biotech company, Procarta Biosystems. As VP Business Development at Astex Therapeutics, he was responsible for more than 13 major collaboration and licensing deals in a period of four years. To date he has executed more than 30 major, in- and out-licensing deals, and company acquisitions, totalling in excess of $1 billion. Nigel held a postdoctoral position at the Institute of Biotechnology, Cambridge University, having obtained his PhD in Molecular Biology from Cambridge University in 1989 and a BSc in Chemistry from the University of Manchester in 1986. He spent his early industrial career as a senior researcher at Cantab Pharmaceuticals, developing a cervical cancer vaccine currently in the clinic. He has also chaired the UK’s BioIndustry Association, Business Development Working Group.

David graduated with a first class degree in Natural Sciences from Cambridge University in 1989 before completing his PhD in Biochemistry at Cambridge in 1992. He is currently a British Heart Foundation Senior Research Fellow directing an internationally recognized group of researchers in the Department of Medicine at Cambridge University in the field of inflammation, with a particular interest in cardiovascular disease. His research has been published in a range of leading peer-reviewed journals including Science, Nature and Nature Medicine, with over 75 scientific publications. David is also an inventor on more than 120 patents and patent applications in the life sciences, ranging from diagnostics to therapeutics. David has run a successful consultancy business, TCP Innovations, and founded more than half a dozen biotechnology companies. He is currently Chief Scientific Officer of Funxional Therapeutics Ltd and sits on the Board of Prolinex Ltd and Protexa Therapeutics Ltd and is a Senior Partner at Total Medical Ventures, a boutique investment group specializing in seed and early stage finance of life sciences companies.

Bill has spent most of the last 25 years in diagnostics during which time he has founded six companies. He was head of R&D at Cambridge Life Sciences before joining Abbott Diagnostics' Technology Acquisition Group in 1993. In 1996 he became CEO of Rowett Research Institute, increasing revenues from £800,000 to £2.1m in 3 years through licensing and research funding. In 1999 he joined ANGLE Technology to head up life science venture activities, where he founded three companies, Nutrition Enhancement Ltd (now Provexis plc), NeuroTargets and the rapid microbiology diagnostics company, Acolyte Biomedica. He left ANGLE to become CEO of Acolyte in 2002, raising £7m in venture capital and launching the BacLite Rapid MRSA product in 2005. In 2007 Acolyte was bought by 3M Healthcare. In 2008 Bill founded Momentum Bioscience, a microbiology diagnostics business focused on early detection of infections in blood and other body sites, of which he is CEO. He also runs his own consultancy, Barford Biosciences Ltd.

Emma Palmer Foster has more than 15 years’ experience in the European pharma and biotech sector, via investment banking, financial communications, investor relations, journalism and technology transfer. She has a broad-based understanding of the issues surrounding the biopharmaceutical sector, bringing a clear external perspective married to communications skills. Following an MA in Biochemistry at Oxford, she worked at Scrip and CRC Technology, followed by seven years as an equities analyst. Later she joined ING to head up Healthcare Corporate Finance. Transaction experience includes the IPOs of XTLBio (£176m), Genetix (£120m) and Tigenix (raising €46m) as well as over €25m of M&A. Following an MBA at Durham Business School, Emma established the financial communications and IR franchise at Northbank Communications, bringing in 19 private and listed clients. EJ Palmer Consulting was established in 2007, and advises companies on corporate and financial strategy, IR and communications, with a wide range of clients. Emma is a Trustee of the mental health charity MPF Counselling and a Visiting Fellow at Durham Business School.

Barnaby is a product commercialisation specialist. Following a first degree in mechanical engineering and masters in biomedical engineering, he spent ten years developing and commercialising innovative assistive technology products. Notable developments include the Smart Wheelchair (winner of the 1998 Gold Award for Innovation in Educational Computing and Technology), the Cameleon 3 communication aid (Millennium Product) and the Bobcat DX elevating powered wheelchair. Following a trade sale in 2000, he exited the two Cambridge-based businesses that he managed and joined GE. He then spent seven years in global strategic marketing roles at GE’s geographical information software business, supporting the telecom and oil and gas industries. In January 2008, Barnaby joined ERBI, the Cambridge-based membership organisation for international life science and healthcare companies. As Medtech Director, he works with ERBI’s member companies, helping them to enhance their global competitiveness.